Viridian Therapeutics Files DEF 14A for FY2024

Ticker: VRDN · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1590750

Sentiment: neutral

Topics: proxy-statement, executive-compensation, corporate-governance

Related Tickers: VRDN

TL;DR

Viridian Therapeutics (VRDN) filed its DEF 14A for 2024, detailing exec pay and governance. Vote your shares!

AI Summary

Viridian Therapeutics, Inc. filed a DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is based in Waltham, MA.

Why It Matters

This filing provides shareholders with crucial information regarding executive compensation, director elections, and other governance proposals, enabling informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and corporate governance, not a material event like an acquisition or earnings miss.

Key Players & Entities

FAQ

What is the primary purpose of a DEF 14A filing?

A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors and executive compensation.

When was this DEF 14A filing submitted by Viridian Therapeutics, Inc.?

This DEF 14A filing was submitted on April 25, 2025.

What is Viridian Therapeutics' fiscal year end date?

Viridian Therapeutics' fiscal year ends on December 31.

Has Viridian Therapeutics, Inc. operated under different names previously?

Yes, the company was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.

Where is Viridian Therapeutics, Inc. headquartered?

Viridian Therapeutics, Inc. is located at 221 Crescent Street, Suite 103A, Waltham, MA 02453.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing